coronary artery disease

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY 09/27/2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research.

Clinical Updates Wellness & Lifestyle

Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial

By MedXY 09/27/2025

The PROMISE trial's 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.

Clinical Updates Wellness & Lifestyle

Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study

By MedXY 09/16/2025

A one-year DASH diet intervention led to sustained suppression of proatherogenic chemokine CXCL4 and fewer major cardiovascular events over six years despite reduced adherence and partial loss of initial benefits in nonobstructive CAD patients.

Clinical Updates Wellness & Lifestyle

Harnessing Machine Learning to Predict High-Risk Coronary Artery Disease: Insights from the SCOT-HEART Trial

By MedXY 09/14/2025

Machine learning models trained on clinical data improve prediction of coronary artery disease on CT scans compared to traditional risk scores, potentially guiding better resource utilization in cardiovascular care.

Medical News Wellness & Lifestyle

Understanding Organ Calcification: When to Worry and What to Do

By MedXY 09/03/2025

Discover the causes of organ calcification, differentiate harmless from dangerous types, and learn how to interpret your health reports with expert advice.

Clinical Updates Wellness & Lifestyle

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.

Cardiology Nephrology Specialties

Comparative Effectiveness of Prasugrel Versus Clopidogrel in Patients with Impaired Renal Function: A Clinical Review

By MedXY 08/21/2025

Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.